Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Corporate - Media & Press – Mark Schena VIP Technology Press Release
Mark Schena, PhD, Positions Arrayit Corporation to Enter Molecular Diagnostics Using VIP Technology
Single Laboratory Test Can Screen up to 100,000 Patients
Source: Arrayit Corporation
Date: Wednesday June 24, 2009, 7:00 am EDT
Arrayit Corporation (OTC.BB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that its patented testing procedure, sold under the trade name Variation Identification Platform (VIP), is ready for distribution and use.
Created by pioneer and Arrayit President, Dr. Mark Schena, VIP is the world's key microarray diagnostics patent that allows clinicians to test up to 100,000 patients against a single disease state health condition by printing that bio-information on a single slide and then drawing a diagnosis for each individual patient. Arrayit is now positioned to move this revolutionary technology from research to clinical applications and beyond.
In 1995, Dr. Schena and colleagues published the first paper on microarrays in the premier scientific journal, Science, introducing microarrays to the world as a new scientific technology. His work rapidly led to a new field of discovery that uses microarrays to investigate both genes and proteins in research and diagnostics. Acknowledged by his peers for the importance of these accomplishments, Dr. Schena was proclaimed the Father of Microarray Technology by The Scientist, a broadly read scientific journal, in 2003.
Today microarrays are used in more than 100,000 laboratories in 50 countries to explore complicated questions in biology, chemistry, agriculture and medicine. The microarray field to date has produced 550,000 scientific publications. The commercial expansion of microarray technologies has created a multi-billion dollar research market with over 200 companies that produce ancillary products and services.
Dr. Schena has authored five foundational books and has published more than 30 important papers. Dr. Schena has organized symposia and course work, chaired societal meetings and promoted the expansion of microarray technology -- accruing over half a million travel miles to speak to audiences of PhDs, MDs and life science professionals.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.